Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Central nervous system involvement in diffuse large B-cell lymphoma.
Yamamoto W, Tomita N, Watanabe R, Hattori Y, Nakajima Y, Hyo R, Hashimoto C, Motomura S, Ishigatsubo Y. Yamamoto W, et al. Among authors: watanabe r. Eur J Haematol. 2010 Jul;85(1):6-10. doi: 10.1111/j.1600-0609.2010.01438.x. Epub 2010 Mar 3. Eur J Haematol. 2010. PMID: 20236301
Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era.
Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Ohshima R, Hatta Y, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Ishigatsubo Y, Takeuchi K. Tomita N, et al. Among authors: watanabe r. Cancer Sci. 2012 Feb;103(2):245-51. doi: 10.1111/j.1349-7006.2011.02139.x. Epub 2011 Nov 29. Cancer Sci. 2012. PMID: 22044593 Free article.
Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
Watanabe R, Tomita N, Itabashi M, Ishibashi D, Yamamoto E, Koyama S, Miyashita K, Takahashi H, Nakajima Y, Hattori Y, Motohashi K, Takasaki H, Ohshima R, Hashimoto C, Yamazaki E, Fujimaki K, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y. Watanabe R, et al. Eur J Haematol. 2014 Mar;92(3):204-10. doi: 10.1111/ejh.12221. Epub 2013 Nov 28. Eur J Haematol. 2014. PMID: 24283206
Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study.
Yamamoto W, Nakamura N, Tomita N, Takeuchi K, Ishii Y, Takahashi H, Watanabe R, Takasaki H, Motomura S, Kobayashi S, Yokose T, Ishigatsubo Y, Sakai R. Yamamoto W, et al. Among authors: watanabe r. Leuk Lymphoma. 2014 Dec;55(12):2721-7. doi: 10.3109/10428194.2014.893311. Epub 2014 Mar 19. Leuk Lymphoma. 2014. PMID: 24528218
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
Tomita N, Takasaki H, Ishiyama Y, Kishimoto K, Ishibashi D, Koyama S, Ishii Y, Takahashi H, Numata A, Watanabe R, Tachibana T, Ohshima R, Hagihara M, Hashimoto C, Takemura S, Taguchi J, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y. Tomita N, et al. Among authors: watanabe r. Leuk Lymphoma. 2015 Mar;56(3):725-9. doi: 10.3109/10428194.2014.931953. Epub 2014 Aug 6. Leuk Lymphoma. 2015. PMID: 24913502
Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy.
Nakajima Y, Tomita N, Itabashi M, Miyashita K, Watanabe R, Miyazaki T, Tachibana T, Takasaki H, Kawasaki R, Tanaka M, Hashimoto C, Yamazaki E, Taguchi J, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Harano H, Motomura S, Ishigatsubo Y. Nakajima Y, et al. Among authors: watanabe r. Leuk Res. 2015 Feb;39(2):198-203. doi: 10.1016/j.leukres.2014.11.030. Epub 2014 Dec 8. Leuk Res. 2015. PMID: 25541027 Clinical Trial.
Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma.
Koyama S, Fujisawa S, Watanabe R, Itabashi M, Ishibashi D, Ishii Y, Hattori Y, Nakajima Y, Motohashi K, Takasaki H, Kawasaki R, Hashimoto C, Yamazaki E, Koharazawa H, Takemura S, Tomita N, Sakai R, Motomura S, Nakajima H. Koyama S, et al. Among authors: watanabe r. Int J Lab Hematol. 2017 Feb;39(1):112-117. doi: 10.1111/ijlh.12592. Epub 2016 Nov 24. Int J Lab Hematol. 2017. PMID: 27885817 Clinical Trial.
Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Watanabe R, Tomita N, Kishimoto K, Koyama S, Ogusa E, Ishii Y, Miyashita K, Matsuura S, Fujisawa S, Hattori Y, Takasaki H, Fujita A, Ohshima R, Kuwabara H, Hashimoto C, Fujimaki K, Sakai R, Ishigatsubo Y. Watanabe R, et al. Leuk Res. 2013 Oct;37(10):1208-12. doi: 10.1016/j.leukres.2013.07.015. Epub 2013 Aug 5. Leuk Res. 2013. PMID: 23927994
[Analysis of prognostic factors in transplant-eligeble newly diagnosed myeloma patients treated with bortezomib plus dexamethasone as induction therapy].
Koharazawa H, Watanabe R, Hattori Y, Numata A, Kawasaki R, Kuwabara H, Hagihara M, Matsumoto K, Tanaka M, Hashimoto C, Takemura S, Yamazaki E, Fujimaki K, Taguchi J, Tomita N, Fujita H, Sakai R, Harano H, Ishigatsubo Y, Fujisawa S. Koharazawa H, et al. Among authors: watanabe r. Rinsho Ketsueki. 2015 Apr;56(4):392-9. doi: 10.11406/rinketsu.56.392. Rinsho Ketsueki. 2015. PMID: 25971269 Japanese.
2,286 results